Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE013 (USA) (Dr. Clarke)
· consented 2022-11-25
Adverse events
4
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 3); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 28); relationship: N
severe
serious
assessed
2026-08-18
Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 48); relationship: not assessed; serious criteria: life-threatening
mild
assessed
2026-08-18
Grade 1 Decreased appetite — outcome: UNKNOWN; onset 2023-02-22 (study day 84); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.